Ultragenyx Pharmaceutical Inc. (RARE) Stock Overview
Explore Ultragenyx Pharmaceutical Inc.’s financial performance, market position, analyst ratings, and future outlook.
Ultragenyx Pharmaceutical Inc. (RARE)
Key Financials
Key Financials
Market Cap
2.2B
P/E Ratio
-3.82
EPS (TTM)
$-6.10
ROE
15.67%
RARE Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Ultragenyx Pharmaceutical Inc. (RARE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 39.87, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $14.15.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.82 and a market capitalization of 2.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.